Clinical trials: Tobacco Smoking Behavior
Stroke, Hypertension
DELPHI in Subjects at Risk for Stroke and Dementia
The DELPhi system is a software device that is used for the noninvasive evaluation of brain plasticity and connectivity. The DELPhi software uses EEG and TMS devices as accessories.
- Conditions
- Stroke, Hypertension, Diabete Mellitus, Dyslipidemias
- Trial name
- NCT03884647
- Testing
- DELPhI system
- Where
- 4 sites in United States, Israel
- Volunteers
- 335 people, healthy volunteers welcome
- Sponsor
- QuantalX Neuroscience
E-cigarette Use, Cigarette Smoking
BIDI Stick ENDS Abuse Liability and Puffing Topography Assessment
This study assessed the abuse liability (measured by assessing how much nicotine enters the body when the BIDI Stick is used, and how this makes users feel) and puffing topography (puff characteristics like volume and duration)…
- Trial name
- NCT05072925
- Testing
- Tobacco products
- Where
- Poland
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- BIDI Vapor
Smoking Behaviors, Smoking ( Cigarette)
A Study to Assess Nicotine Uptake From Electronic Nicotine Delivery System Products
This will be a randomized, open-label, 8-way crossover, single-site study designed to evaluate elements of abuse liability (AL), including subjective effects and physiological measures (pharmacodynamics [PD]), and plasma nicotine…
- Conditions
- Smoking Behaviors, Smoking ( Cigarette), Tobacco Use
- Trial name
- NCT07739797
- Testing
- Golden Tobacco Chill 5% (4) 6.5W, Glacier Menthol 5% (4) 6.5W, Fresh Mint 5% (4) 6.5W
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- RAI Services Company
Tobacco Use, Smoking
CSD231005 Nicotine Pouch Biomarkers of Exposure
This will be a multi center open label, randomized, controlled, switching parallel-group study designed to assess changes in select biomarkers of exposure (BoE) in generally healthy smokers following a 5 day in-clinic switch to…
- Trial name
- NCT06303115
- Testing
- Nicotine Pouch P1312914, 4 mg nicotine, Nicotine Pouch P1312915, 8 mg nicotine, Nicotine Pouch P1013215, 8 mg nicotine
- Where
- 5 sites in United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- RAI Services Company
Smoking, Tobacco, Smoking Behaviors
Post-Market Surveillance of Tobacco Products
This is a multicenter, post market surveillance study designed to evaluate biomarkers of tobacco exposure and effect, health status measurements, and tobacco product usage patterns in subjects who are natural adopters of…
- Trial name
- NCT04255459
- Testing
- Moist Snuff, Camel Snus, Cigarettes
- Where
- 6 sites in United States
- Volunteers
- 320 people, healthy volunteers welcome
- Sponsor
- RAI Services Company
Smoking, Smoking Cessation
Evaluation of the Nicotine Lozenge in Relief of Provoked Acute Craving
This study is designed to evaluate the ability of a nicotine lozenge to relieve craving for a cigarette compared to a matched placebo (a placebo is like sugar pill and contains no active).
- Trial name
- NCT01466361
- Testing
- Nicotine lower dose, Nicotine higher dose
- Where
- United States
- Volunteers
- 187 people
- Sponsor
- GlaxoSmithKline
Tobacco Use Disorder, Tobacco Dependence
Study to Evaluate the Safety and Efficacy of Dietary Supplement Anatabloc in Reducing Daily Smokers' Urge to Smoke
This study will consist of 2 phases. Phase 1 will be a one day crossover study to see the effects of study product on a smoker's desire to smoke, measured by changes in scores on questionnaires given over time.
- Conditions
- Tobacco Use Disorder, Tobacco Dependence, Smoking
- Trial name
- NCT01428310
- Testing
- Anatabloc(TM), CigRx(R)
- Where
- United States
- Volunteers
- 109 people, healthy volunteers welcome
- Sponsor
- Rock Creek Pharmaceuticals, Inc.
Smoking, Tobacco
Carbon Monoxide Breath Sensor System Performance, Human Factors, and Usability Assessment Conducted in a Single Visit
Prospective, open label, single center clinical study enrolling 70 subjects to study Performance, Human Factors, and Usability for the Carbon Monoxide Breath Sensor System (COBBS)
- Trial name
- NCT03148613
- Testing
- Carbon Monoxide Breath Sensor System (COBSS), Bedfont - Micro+™ Smokerlyzer®
- Where
- United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- David Utley, MD
Smoking Cessation
A 52-Week Multicenter Study Evaluating the Safety and Efficacy of Varenicline for the Maintenance of Smoking Cessation
The primary purpose of this study is a comparison of abstinence maintenance in subjects randomized to double-blind varenicline or placebo from Weeks 13 -24 in subjects who responded to an intial 12-week open label course of…
- Trial name
- NCT00143286
- Testing
- varenicline (CP-526,555)
- Where
- 24 sites in United States, Canada and 5 more
- Volunteers
- 2,000 people
- Sponsor
- Pfizer
Smoking Cessation, Pharmacokinetics
A Clinical Trial to Compare Pharmacokinetics of the "CDFF0318" and "Champix Tab. 1mg"
A Phase 1 Clinical Trial to Compare and Evaluate Safety and Pharmacokinetic Characteristics after Administration of the "CDFF0318" and "Champix Tab. 1mg (Varenicline tartrate)" in Healthy Male Volunteers
- Trial name
- NCT04631874
- Testing
- CDFF0318, Champix
- Where
- South Korea
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- CTC Bio, Inc.
Smoking Cessation
A Study of Cytisinicline for Smoking Cessation in Adult Smokers
This placebo-controlled Phase 3 study is being conducted at sites within the United States to evaluate 3 mg cytisinicline 3 times daily (TID) for treatment duration of 42 days/6 weeks and evaluate 3 mg cytisinicline TID for…
- Trial name
- ORCA-2 (NCT04576949)
- Testing
- Cytisinicline, Behavioral support
- Where
- 17 sites in United States
- Volunteers
- 810 people
- Sponsor
- Achieve Life Sciences
Smoking Cessation
Randomized Trial to Evaluate the Effectiveness of X-22 as a Smoking Cessation Aid
A randomized, active controlled clinical trial in which a total of 216 healthy smokers will be enrolled and followed over approximately 19 weeks.
- Trial name
- NCT01400815
- Testing
- X-22 Smoking Cessation Product, Active Control Cigarettes
- Where
- 3 sites in United States
- Volunteers
- 234 people
- Sponsor
- 22nd Century Limited, LLC
Smoking Cessation
A Study to Evaluate the Effect of Lorcaserin Hydrochloride on Smoking Cessation
In smokers who are motivated to stop smoking, treatment with lorcaserin compared with placebo will provide greater abstinence as measured by the last 4 weeks of treatment (Weeks 9-12). The target quit date was Day 15.
- Trial name
- NCT02044874
- Testing
- APD356-lorcaserin hydrochloride
- Where
- 31 sites in United States
- Volunteers
- 603 people
- Sponsor
- Arena Pharmaceuticals
Smoking Cessation
12 Week Evaluation of the Safety and Efficacy of 3 Doses of CP-526,555 and Placebo for Smoking Cessation
The purpose of the study is to examine the safety and efficacy and dose-response relationship of three doses of CP-526,555 for 12 weeks compared with placebo for smoking cessation; including post-treatment follow-up of smoking…
- Trial name
- NCT00139750
- Testing
- CP-526,555 (varenicline)
- Where
- 15 sites in Japan
- Volunteers
- 600 people
- Sponsor
- Pfizer
Smoking
CSD1602: A Crossover Study to Evaluate the Exposure to "Tar" and Nicotine From Two King Size Menthol Cigarette Products
This study will evaluate exposure to "tar" and nicotine from two menthol cigarette products and provide a basis for comparing mouth-level exposure when smokers smoke the two cigarette products.
- Trial name
- NCT03063034
- Testing
- PD21864AA, PD21864AB
- Where
- United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- RAI Services Company
Smoking Cessation, Nicotine Replacements Therapy
A Study of Nicotine Orodispersible Tablet on Craving Relief of Male and Female Smoker Volunteers
The objective of the study is to evaluate the relief of momentary urge to smoke at pre-specified early post-dose time points after administration of Nic ODT compared to Placebo ODT.
- Trial name
- Zippy PD (NCT07893158)
- Testing
- Nicotine Mint Oro Dispersible Tablet (Nic ODT)
- Where
- Canada
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- McNeil AB
Cardiovascular Diseases, Smoking
Effect of Switching From Cigarette Smoking to THS on Systemic Endothelial Function in Subjects With Established Atherosclerotic Disease
The purpose of this study is to demonstrate improvement in flow mediated dilation (FMD), a functional endpoint associated with the progression of atherosclerosis, when switching from cigarettes to the Tobacco Heating System (THS)…
- Conditions
- Cardiovascular Diseases, Smoking, Tobacco Use, Peripheral Arterial Disease
- Trial name
- NCT05566678
- Testing
- Cigarette, THS, Smoking Abstinence
- Sponsor
- Philip Morris Products S.A.
Chronic Obstructive Pulmonary Disease (COPD)
Aclidinium/Formoterol Fixed Combination Dose Finding Study
The study seeks to determine the optimal dose of the Aclidinium/Formoterol combination for investigation in Phase III clinical trials
- Trial name
- NCT00626522
- Testing
- Aclidinium bromide and formoterol
- Where
- 9 sites in Australia, Czechia and 2 more
- Volunteers
- 808 people
- Sponsor
- AstraZeneca
Bullying, Cyberbullying
Using Digital Health Technology to Prevent Bullying and Cyberbullying Among Elementary School Students
This project is designed to address the urgent need for an effective primary prevention approach to the problem of bullying and cyberbullying among elementary school students.
- Conditions
- Bullying, Cyberbullying, Smoking
- Trial name
- NCT06592872
- Testing
- Bullying prevention
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Christopher Williams
Smoking Cessation
A Study Evaluating The Absorption Of Varenicline Into The Body From A Varenicline Solution And A Varenicline Patch Applied To The Skin
To evaluate the absorption, safety, and tolerability of a varenicline solution and a varenicline patch applied to the skin.
- Trial name
- NCT00774605
- Testing
- Varenicline free base solution, Varenicline free base patch
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Pfizer